Structure Therapeutics Inc. (GPCR)

Price$39.55Cached quoteAs of 2026-09-11 13:39 UTC

AI: Fair-priced

Price checkThe market already assigns substantial value to an unapproved drug program, despite the large cash reserve.

At the observed quote, GPCR's equity value is about $3.34 billion. June 30 liquid resources—cash, cash equivalents and short-term investments—were $1.34 billion, while total liabilities were about $71 million, leaving investors paying roughly $2.0 billion above liquid resources for the pipeline. Shareholders' equity, meaning assets minus liabilities, was $1.35 billion, so the stock trades near 2.5 times book value. With no product revenue, that premium looks meaningful but not extreme given positive obesity data. That balance supports a Fair-priced verdict, not a bargain. StockAnalysis.com+1

Big pictureA strong balance sheet can fund major trials, but the business still consumes cash rather than producing it.

Structure remains pre-revenue and loss-making. The supplied SEC history shows a 2025 net loss of $141.2 million and operating cash outflow of $222.2 million; in Q2 2026 the net loss widened to $106.2 million from $61.7 million a year earlier as research spending nearly doubled to $100.1 million. Against that burn, June 30 liquid resources were $1.34 billion, which management says should fund planned operations and key clinical milestones through 2028, although commercial manufacturing and some pre-launch costs are excluded from that runway estimate. Structure Therapeutics+1

Business strengthThe lead pill has competitive weight-loss results, while cash funding reduces near-term financing pressure.

Aleniglipron produced placebo-adjusted weight loss up to 16.3% at 44 weeks in ACCESS II, and later extension data showed continued loss up to 16.2% with a 10.4% overall discontinuation rate and no reported drug-induced liver injury. Those results are strong enough to justify two global late-stage trials enrolling up to 4,700 people. The counterweight is competition: Lilly's oral Foundayo is already approved in the United States, so Structure must prove not just efficacy, but tolerability, durability and a commercially useful difference before approval can create cash flow. Reuters+2Reuters+2

What could change the storyLate-stage results can justify the pipeline premium, while weak safety or efficacy would erase it quickly.

Unlike a cyclical business, value depends mainly on trial readouts. Two things matter most. First, ACCOMPLISH must confirm earlier weight loss and safety over 76 weeks in much larger populations; successful results would sharply reduce clinical uncertainty and could support regulatory filings. Second, dilution must stay controlled. Ordinary shares outstanding rose from about 171.9 million at the end of 2024 to 212.5 million at the end of 2025, helped by a December offering that raised about $701.5 million net. The company bought runway at a strong price, but repeated large raises would spread future drug value across more shares. ClinicalTrials+2Structure Therapeutics+2

AI: News

Phase 3 dosing beginsStructure started two pivotal obesity trials, moving aleniglipron from promising data into registration-focused testing.

On August 6, Structure said first patients had been dosed in ACCOMPLISH-1 and ACCOMPLISH-2. The studies plan to enroll up to 3,600 and 1,100 participants, respectively, testing three maintenance doses against placebo. This matters because the program is designed to support global regulatory submissions. It also begins a much more expensive stage of development, making the company's $1.34 billion liquid reserve and 2028 runway central to the investment case. Structure Therapeutics

Safety and durability updateLonger follow-up kept weight loss moving and eased a key liver-safety concern before late-stage trials.

On June 5, Nature Medicine and conference data showed continued weight loss beyond 36 weeks, reaching up to 16.2% in the open-label extension. Reuters reported no signs of drug-induced liver injury and a 10.4% overall discontinuation rate, while gastrointestinal side effects remained common. The update mattered because investors had been focused on whether oral obesity drugs could combine strong efficacy with acceptable tolerability; the data supported the lower starting-dose design later used in the pivotal program. Structure Therapeutics+1

ACCESS II toplineHigher-dose data showed roughly sixteen percent placebo-adjusted weight loss and lifted the shares nearly nine percent.

On March 16, Structure reported placebo-adjusted mean weight loss of 16.3% at 180 milligrams and 16.0% at 240 milligrams after 44 weeks, with no evidence of a weight-loss plateau. Reuters said the shares rose nearly 9% after the announcement. The result strengthened the case that aleniglipron could compete with injectable medicines and other oral pills, while still leaving the larger pivotal trials to confirm safety, durability and real-world commercial differentiation. Reuters

Loading local price history

Revenue

2022

2023

2024

2025

Net income

2022

2023

2024

2025

Free cash flow

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022
Revenue	$0	$0	$0	$0
Research & development	$225.3M	$108.8M	$70.1M	$36.2M
Operating expenses	$176.6M	$158.2M	$102.8M	$52.6M
Operating income	−$176.6M	−$158.2M	−$102.8M	−$52.6M
EBITDA	−$175.2M	−$157.2M	−$102.5M	−$52.3M
Net income	−$141.2M	−$122.5M	−$89.6M	−$51.3M
Basic EPSper basic share	-$0.80	-$0.78	-$0.81	-$5.51
Diluted EPSper diluted share	-$0.80	-$0.78	-$0.81	-$5.51

Review official source filings ↗

Insider buys & sells

Jul 1, 2024–Jun 30, 2026

Buys0$0.00 disclosed value

Sells (SEC code S)23$7.04M disclosed value

Transaction	Insider	Type	Shares	Price	Value	Owned after
Jun 25, 2026Form 4 · 10b5-1	Lin XichenCHIEF SCIENTIFIC OFFICER	SellAmerican Depositary Shares · derivative	7.9K	$49.08	$386.7K	0
Apr 14, 2026Form 4	FMR LLCTenPercentOwner,Other	SellAmerican Depositary Shares · derivative · indirect	16.1K	$55.07	$885.8K	32.2K
Apr 14, 2026Form 4	FMR LLCTenPercentOwner,Other	SellAmerican Depositary Shares · derivative · indirect	1.4K	$55.07	$75.3K	2.7K
Jan 15, 2026Form 4	FMR LLCTenPercentOwner,Other	SellAmerican Depositary Shares · derivative · indirect	230	$85.04	$19.6K	48.3K
Jan 15, 2026Form 4	FMR LLCTenPercentOwner,Other	SellAmerican Depositary Shares · derivative · indirect	6.5K	$84.22	$547.3K	48.5K

Review ownership filings at SEC.gov ↗

Community posts

View community

@tickerstat3 days ago
Structure reports up to 16.2% weight loss in extended obesity study
Structure Therapeutics ($GPCR) reported up to 16.2% average body-weight reduction at 72 weeks in an open-label extension study of aleniglipron, its experimental oral GLP-1 treatment. Participants in the highest-performing group had escalate ...
0
0

Structure Therapeutics Inc. (GPCR)

Financial charts

Financial statements

Insider buys & sells

Community posts

Structure reports up to 16.2% weight loss in extended obesity study